A GHRH analog + GHRP combination that hits two separate pathways simultaneously — producing synergistic GH release that consistently outperforms either peptide alone.
CJC-1295 / Ipamorelin is a peptide combination — two compounds used together that work on complementary sides of the growth hormone (GH) release pathway. It's the most widely researched peptide stack for GH optimization, largely because the combination produces significantly greater GH release than either compound alone.
CJC-1295 (most commonly the without-DAC version, also called Mod GRF 1-29) is a GHRH analog — it mimics the signal your hypothalamus sends to your pituitary to release GH. Ipamorelin is a GHRP (growth hormone-releasing peptide) — it mimics ghrelin to trigger GH release through a separate receptor pathway while also suppressing somatostatin, the hormone that inhibits GH release.
GHRH (CJC-1295) tells the pituitary to produce and release GH. GHRP (Ipamorelin) simultaneously suppresses the brake on GH release (somatostatin) while providing an independent stimulation signal. The combination creates a synergistic effect — studies consistently show the GHRH + GHRP combination produces 2–10x more GH than either peptide alone.
CJC-1295 (without DAC / Mod GRF 1-29) is a 29-amino-acid modified analog of GHRH. It binds GHRH receptors on pituitary somatotroph cells, activating the cAMP pathway to stimulate GH synthesis and release. Its half-life (~30 minutes) is designed to match the natural GHRH pulse — producing a sharp, physiological spike rather than sustained elevation.
The "with DAC" version (Drug Affinity Complex) extends the half-life to 6–8 days, producing sustained GH elevation rather than a pulse. Most research protocols use the without-DAC version specifically to preserve pulsatile GH release patterns.
Ipamorelin is a selective GH secretagogue — it activates the ghrelin receptor (GHSR-1a) on the pituitary and hypothalamus. This does two things: it provides an independent stimulatory signal for GH release and simultaneously suppresses somatostatin (the inhibitory signal). Ipamorelin is considered the "cleanest" GHRP because it produces minimal cortisol or prolactin elevation compared to other GHRPs like GHRP-6 or GHRP-2.
Even when CJC-1295 signals the pituitary to release GH, somatostatin can partially blunt that response. Ipamorelin removes this brake — it's why the combination consistently outperforms GHRH-only protocols in research. You're simultaneously pressing the accelerator (CJC-1295) and releasing the brakes (Ipamorelin).
| Factor | CJC-1295 / Ipamorelin | Sermorelin |
|---|---|---|
| Components | Two peptides (GHRH + GHRP) | Single GHRH analog |
| GH output | Significantly greater (synergy) | Moderate — GHRH only |
| Somatostatin suppression | Yes (Ipamorelin) | No |
| Half-life (CJC no DAC) | ~30 min / ~2 hrs | ~11 min |
| Protocol complexity | Two compounds, same injection | Single compound |
| Selectivity | Ipamorelin is highly selective (no cortisol) | Single receptor target |
| Cost | Higher (two compounds) | Lower |
| FDA history | None | Approved 1997 (Geref) |
COA-verified vendor pricing with promo codes from S1 Research and Tegridy Research.
View Pricing → Dosage Calculator